Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes

Affiliations

¹ Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
² Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, China.

Published Erratum

Li Chen et al. Front Pharmacol. 2022.

. 2022 Nov 14:13:1079635.

doi: 10.3389/fphar.2022.1079635. eCollection 2022.

¹ Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
² Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.836958.].

Keywords: PD-1; PD-L1; controlling nutritional status; gastric cancer; immune checkpoint inhibitors.

Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes.
Chen L, Sun H, Zhao R, Huang R, Pan H, Zuo Y, Zhang L, Xue Y, Song H, Li X. Chen L, et al. Front Pharmacol. 2022 Mar 4;13:836958. doi: 10.3389/fphar.2022.836958. eCollection 2022. Front Pharmacol. 2022. PMID: 35308215 Free PMC article.